{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T14:22:20Z","timestamp":1774448540487,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005898","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de M\u00e9decine Vasculaire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005898","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Diseases"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vasdi.2026.01.134","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:54:06Z","timestamp":1770900846000},"page":"77-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["How French vascular physicians treat cancer associated superficial vein thrombosis?"],"prefix":"10.1016","volume":"51","author":[{"given":"Simon","family":"Soudet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Khider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Mirault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Antoinette","family":"Sevestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vasdi.2026.01.134_bib0090","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/jth.12575","article-title":"Annual diagnosis rate of superficial vein thrombosis of the lower limbs: the STEPH community-based study","volume":"12","author":"Frapp\u00e9","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1160\/TH10-06-0406","article-title":"Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis. The OPTIMEV study","volume":"105","author":"Galanaud","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0100","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1056\/NEJMoa0912072","article-title":"Fondaparinux for the treatment of superficial-vein thrombosis in the legs","volume":"363","author":"Decousus","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0105","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2352-3026(17)30014-5","article-title":"Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial","volume":"4","author":"Beyer-Westendorf","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0110","first-page":"162","article-title":"Unresolved questions on venous thromboembolic disease. Therapeutic management of superficial vein thrombosis (SVT). Consensus statement of the French Society for Vascular Medicine (SFMV)","volume":"49","author":"Sevestre","year":"2024","journal-title":"J Med Vasc"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.acvd.2023.11.010","article-title":"Anticoagulant treatment of cancer-associated thromboembolism","volume":"117","author":"Mah\u00e9","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0120","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1182\/blood-2018-03-837153","article-title":"Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP)","volume":"132","author":"Decousus","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0125","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3390\/cancers15072034","article-title":"Three-month outcomes in cancer patients with superficial or deep vein thrombosis in the lower limbs: results from the RIETE registry","volume":"15","author":"Debourdeau","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0130","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.thromres.2018.04.013","article-title":"Long-term outcomes of isolated superficial vein thrombosis in patients with active cancer","volume":"171","author":"Galanaud","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0135","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/0268355520982456","article-title":"Management of superficial venous thrombosis in unevaluated situations: cancer, severe renal impairment, pregnancy and post-partum","volume":"36","author":"Ghenassia-Fouillet","year":"2021","journal-title":"Phlebology"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0140","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00063198-200309000-00009","article-title":"Superficial vein thrombosis: risk factors, diagnosis, and treatment","volume":"9","author":"Decousus","year":"2003","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0145","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.rmr.2019.01.003","article-title":"Recommandations de bonne pratique pour la prise en charge de la maladie veineuse thromboembolique chez l\u2019adulte. Version courte","volume":"36","author":"Sanchez","year":"2019","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0150","first-page":"e1","article-title":"[Unresolved questions on venous thromboembolic disease. Consensus statement of the French Society for Vascular Medicine (SFMV)]","volume":"44","author":"Qu\u00e9r\u00e9","year":"2019","journal-title":"J Med Vasc"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2022.10.022","article-title":"Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice","volume":"220","author":"Langer","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0160","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0165","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vasdi.2026.01.134_bib0170","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/0897190017722873","article-title":"Evaluation of direct-acting oral anticoagulant use in patients with cancer","volume":"31","author":"Davis","year":"2018","journal-title":"J Pharm Pract"}],"container-title":["Vascular Diseases"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050658126001342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050658126001342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:48:21Z","timestamp":1774442901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050658126001342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S3050658126001342"],"URL":"https:\/\/doi.org\/10.1016\/j.vasdi.2026.01.134","relation":{},"ISSN":["3050-6581"],"issn-type":[{"value":"3050-6581","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How French vascular physicians treat cancer associated superficial vein thrombosis?","name":"articletitle","label":"Article Title"},{"value":"Vascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vasdi.2026.01.134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}